Guest Editor(s)

• Prof. Giovanni Targher, MD

  Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

  Website | E-mail

• Dr. Alessandro Mantovani, MD

  Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

  Website | E-mail

Special Issue Introduction

During these two years of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, it has become increasingly clear that about 50% of patients who died from Coronavirus disease 2019 (COVID-19) had metabolic disorders, mainly obesity, type 2 diabetes, hypertension, or non-alcoholic fatty liver disease. Notably, experimental and observational studies have reported a complex and bidirectional relationship between COVID-19 and metabolic disorders. Indeed, on one side, patients with diabetes or other metabolic disorders have a higher risk of severe illness from COVID-19 and greater in-hospital mortality than those without metabolic disorders and, on the other side, COVID-19 may contribute to worse pre-existing metabolic disorders or even lead to new-onset diabetes or other metabolic disorders.

This Special issue of Metabolism and Target Organ Damage will focus on new experimental and epidemiological data in the area of the bidirectional links between COVID-19 and metabolic disorders. In particular, it will cover a selection of research and review articles on the following potential issues:

Predisposition to severe illness from COVID-19 in patients with metabolic disorders;
Effect of COVID-19 on metabolic and endocrine systems;
Effect of environmental, economic, and social factors on the link between COVID-19 and metabolic disorders;
Metabolic pathways possibly related to susceptibility and severity of COVID-19;
Molecular mechanisms underpinning the link between COVID-19 and metabolic disorders;
Role of nutritional status on the variability of COVID-19 susceptibility, course, and response to treatment;
Long-term metabolic consequences of COVID-19;
Effect of glucose-lowering medications on COVID-19 outcomes;
Metabolic disorders and vaccine-breakthrough SARS-CoV-2 infection;
Changes of thinking and management of metabolic diseases during and after the SARS-CoV-2 pandemic.

Experimental papers, epidemiological papers, up-to-date review articles, systematic reviews and meta-analyses, and commentaries are all welcome.

I hope you enjoy reading this edition of the journal.

Participants

1. Saula Vigili de Kreutzenberg, Department of Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy.
2. Giovanni Guaraldi, Infectious Diseases Unit, University Hospital of Modena, Modena, Italy.
3. Luca Miele, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy.

Submission Deadline

15 Oct 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://mtodjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mtod&SpecialIssueId=mtod211228
Submission Deadline: 15 Oct 2022
Contacts: Doreen Deng, Managing Editor, editorialoffice@mtodjournal.net
                  Zoe Zhang, Assistant Editor, zoe@mtodjournal.net